Our Q2 2024 sales and earnings report
July 30, 2024
Merck’s (NYSE: MRK) Q2 2024 results demonstrate strong business momentum and further progress in our diverse pipeline. Our company announced worldwide sales of $16.1 billion, an increase of 7% from Q2 2023.
“Our business is demonstrating strong momentum as we exit the first half of the year,” said Rob Davis, chairman and chief executive officer. “Through excellent scientific, commercial and operational execution, we’re achieving significant milestones for our company and for patients. I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as we continue delivering innovation that solves unmet medical needs.”
Merck anticipates full-year 2024 worldwide sales to be between $63.4 billion and $64.4 billion.
Find more details on Q2 2024 results below.
